Leerink Swann Reiterates on Aegerion Pharmaceuticals as Weakness is Overdone UPDATE: Leerink Swann Initiates Coverage on WellPoint as There is Upside Amid the Winds of Change UPDATE: Leerink Swann ...

In a dramatic turnaround from bankruptcy court less than two years ago, Leerink Partners is now on the offensive and hiring ...

Moderna's (NASDAQ:MRNA) mRNA-1647, its vaccine asset for cytomegalovirus (CMV), may not yield positive interim phase 3 data when it could be released by the end of the month, according to Leerink.

Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.64) per share.

Leerink analyst Joseph Schwartz notes Outperform-rated Sarepta (SRPT) disclosed two-year Part 1 and one-year Part 2 data from the EMBARK study with Elevidys. The firm views these topline results ...

Elevance Health, Inc. (NYSE:ELV – Free Report) – Investment analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for shares of Elevance Health in a research note issued to investors ...

Upstart investment bank SVB Leerink is no longer keeping mum on its ambitions to push into the red hot technology, media, and telecommunications market. The dealmaking unit of SVB Financial Group ...

Leerink lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $6 from $8 and keeps an Outperform rating on the shares after the company announced initial Phase 1b/2 MyPEAK-1 data for ...

Leerink notes that Eli Lilly (LLY) lowered its Q4 total revenue guidance by 5% but issued initial 2025 revenue guidance 2% above consensus. Q4 Mounjaro and Zepbound sales were approximately 18% ...

On Monday, Leerink Partners sustained their Outperform rating and $110.00 price target for Axsome Therapeutics (NASDAQ:AXSM) shares. The firm's stance comes in the wake of recent clinical trial ...